FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311732170> ?p ?o ?g. }

• W4311732170 abstract "Abstract Background Prophylaxis with levofloxacin to prevent bacteremia in certain high-risk oncologic populations has been standard of care since the 2018 publication from the Children’s Oncology Group (JAMA 2018; 320(10)). This study only had susceptibility data for a minority of isolates and did not assess unit-wide impact on development of resistance, an important outcome given fluoroquinolones (FLQs) lead to resistance not only to FLQs but other drug classes, and not only for patients receiving fluoroquinolones rather unit wide. Our objective was to evaluate the development of resistance unit wide after implementing FLQ prophylaxis in our high-risk oncology patients, in addition to evaluating the overall impact on bacteremia. Methods A 6-year (1/2016-12/2021) single-center, retrospective review rates of bacteremia and susceptibility data from the Children’s Hospital Colorado Center for Cancer and Blood Disorders, encompassing the FLQ prophylaxis initiation date of 11/2018. All positive blood cultures were extracted from Meditech® or EPIC Beaker®, and susceptibility data from Microscan® or Sensititer®, with Institutional review board approval. Repeat cultures were not included. All data was analyzed using descriptive statistics performed in Excel®. Results Within the defined study period, there were 199 total blood cultures. These data were normalized per 1000 central line days, and analysis suggests there has been no significant change in bacteremia rates after implementing levofloxacin prophylaxis. Organisms reported nonsusceptible to levofloxacin or ciprofloxacin rose from over 11% in 2016 to almost 46% in 2021. Comparison of trends before and after the 2018 change reveals a significant difference in percent nonsusceptibility for those antibiotics (p = 0.02). Ceftriaxone or cefotaxime and cefepime were also analyzed and while not statistically significant there was a trend toward increasing resistance for ceftriaxone or cefotaxime (Figures). Conclusion Bacteremia on the oncology unit did not decrease after the implementation FLQ prophylaxis in November 2018. Additionally, resistance to FLQ and other antimicrobial classes is increasing, calling into question the benefit of this practice. Disclosures All Authors: No reported disclosures." @default.
• W4311732170 created "2022-12-28" @default.
• W4311732170 creator A5021081447 @default.
• W4311732170 creator A5033627252 @default.
• W4311732170 creator A5041369813 @default.
• W4311732170 creator A5086010950 @default.
• W4311732170 creator A5087379943 @default.
• W4311732170 date "2022-12-01" @default.
• W4311732170 modified "2023-10-17" @default.
• W4311732170 title "556. Evaluation of Antimicrobial Susceptibility Patterns Following Implementation of Levofloxacin Prophylaxis in those with Cancer and Blood Disorders" @default.
• W4311732170 doi "https://doi.org/10.1093/ofid/ofac492.609" @default.
• W4311732170 hasPublicationYear "2022" @default.
• W4311732170 type Work @default.
• W4311732170 citedByCount "0" @default.
• W4311732170 crossrefType "journal-article" @default.
• W4311732170 hasAuthorship W4311732170A5021081447 @default.
• W4311732170 hasAuthorship W4311732170A5033627252 @default.
• W4311732170 hasAuthorship W4311732170A5041369813 @default.
• W4311732170 hasAuthorship W4311732170A5086010950 @default.
• W4311732170 hasAuthorship W4311732170A5087379943 @default.
• W4311732170 hasBestOaLocation W43117321701 @default.
• W4311732170 hasConcept C121608353 @default.
• W4311732170 hasConcept C126322002 @default.
• W4311732170 hasConcept C177713679 @default.
• W4311732170 hasConcept C2778512257 @default.
• W4311732170 hasConcept C2779443120 @default.
• W4311732170 hasConcept C2779473907 @default.
• W4311732170 hasConcept C2781276175 @default.
• W4311732170 hasConcept C501593827 @default.
• W4311732170 hasConcept C71924100 @default.
• W4311732170 hasConcept C86803240 @default.
• W4311732170 hasConcept C89423630 @default.
• W4311732170 hasConceptScore W4311732170C121608353 @default.
• W4311732170 hasConceptScore W4311732170C126322002 @default.
• W4311732170 hasConceptScore W4311732170C177713679 @default.
• W4311732170 hasConceptScore W4311732170C2778512257 @default.
• W4311732170 hasConceptScore W4311732170C2779443120 @default.
• W4311732170 hasConceptScore W4311732170C2779473907 @default.
• W4311732170 hasConceptScore W4311732170C2781276175 @default.
• W4311732170 hasConceptScore W4311732170C501593827 @default.
• W4311732170 hasConceptScore W4311732170C71924100 @default.
• W4311732170 hasConceptScore W4311732170C86803240 @default.
• W4311732170 hasConceptScore W4311732170C89423630 @default.
• W4311732170 hasIssue "Supplement_2" @default.
• W4311732170 hasLocation W43117321701 @default.
• W4311732170 hasOpenAccess W4311732170 @default.
• W4311732170 hasPrimaryLocation W43117321701 @default.
• W4311732170 hasRelatedWork W1968908160 @default.
• W4311732170 hasRelatedWork W1985009402 @default.
• W4311732170 hasRelatedWork W2106139844 @default.
• W4311732170 hasRelatedWork W2119060115 @default.
• W4311732170 hasRelatedWork W2130327235 @default.
• W4311732170 hasRelatedWork W2529399269 @default.
• W4311732170 hasRelatedWork W2797194074 @default.
• W4311732170 hasRelatedWork W3083973191 @default.
• W4311732170 hasRelatedWork W4296807176 @default.
• W4311732170 hasRelatedWork W4313681008 @default.
• W4311732170 hasVolume "9" @default.
• W4311732170 isParatext "false" @default.
• W4311732170 isRetracted "false" @default.
• W4311732170 workType "article" @default.